ProBio CDMO

ProBio CDMO ProBio is proactively providing end-to-end CDMO service from drug discovery to commercialize

Program CD47, provided the service by GenScript ProBio to InnobationBio, will further be advanced by the joint venture...
12/05/2022

Program CD47, provided the service by GenScript ProBio to InnobationBio, will further be advanced by the joint venture between Liminatus Pharma LLC and Iris Acquisition Corp

Dr. Brian Hosung Min, CEO of GenScript ProBio said, “GenScript ProBio is committed to helping customers shorten the timeline for the development of biological drugs, significantly lowering R&D costs and shaping a healthier future. We are very pleased that this promising project will further be advanced by the joint venture between Pharma LLC and Iris Acquisition Corp. GenScript ProBio expects more patients will benefit from these two superior treatments.”

Learn more via https://www.genscriptprobio.com/program-cd47-provided-the-cmc-service-by-genscript-probio-to-innobationbio-will-further-be-advanced-by-the-joint-venture-between-liminatus-pharma-llc-and-iris-acquisition-corp.html?utm_source=fb&utm_campaign=cd47&utm_medium=social

Join us for a 60 minutes webinar to know more about bi-specific strategies including cell line development, upstream...
12/02/2022

Join us for a 60 minutes webinar to know more about bi-specific strategies including cell line development, upstream process development, downstream process development, and analytical method development.

Tuesday | December 6th, 2022 | 10:00 AM ET

Ian Chan (CEO of Abpro) and Rubin Jiang (Director of antibody process development & MSAT group of GenScript ProBio) will be on hand to give you a look at -enabling CMC Strategies for Bispecific Antibodies.

Register here: https://lnkd.in/dFdgBB4d

Join this webinar to learn more about the development of an exciting new and -enabling Strategies for and Time: ...
12/01/2022

Join this webinar to learn more about the development of an exciting new and -enabling Strategies for and

Time: 2022.12.06 16:00-17:30 (AEDT)
Topic 1: Development of an exciting new radioimmunotherapy for cancer patients
Speaker 1: Dr Brad Walsh, CEO, GlyTherix Ltd

Topic 2: IND-enabling CMC Strategies for mAb and bsAb: Faster and Better
Speaker 2: Rubin Jiang, Director of Antibody Process Development & MSAT , GenScript ProBio
Details and Register link:
https://www.genscriptprobio.com/webinars/do-not-miss-genscript-probio-and-glytherix-live-webinar-on-06-december.html?utm_source=fb&utm_campaign=webinar&utm_medium=social

Address

Building 9, 311 Pennington Rocky Hill Rd
Pennington, NJ

Telephone

+17328859188

Website

Alerts

Be the first to know and let us send you an email when ProBio CDMO posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to ProBio CDMO:

Shortcuts

Share